ArriVent BioPharma (AVBP) Expected to Announce Earnings on Thursday

ArriVent BioPharma (NASDAQ:AVBP) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.8463) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 9:30 AM ET.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.09. On average, analysts expect ArriVent BioPharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

ArriVent BioPharma Price Performance

Shares of NASDAQ:AVBP opened at $21.95 on Wednesday. ArriVent BioPharma has a 1 year low of $15.47 and a 1 year high of $27.22. The company has a market capitalization of $970.19 million, a PE ratio of -4.98 and a beta of 0.99. The business has a fifty day moving average price of $22.99 and a two-hundred day moving average price of $21.28.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of ArriVent BioPharma in a research report on Monday, December 22nd. They set an “overweight” rating for the company. B. Riley Financial lifted their price objective on shares of ArriVent BioPharma from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. BTIG Research assumed coverage on shares of ArriVent BioPharma in a research note on Thursday, March 12th. They issued a “buy” rating and a $42.00 target price on the stock. Oppenheimer reissued an “outperform” rating and set a $50.00 target price (up from $44.00) on shares of ArriVent BioPharma in a research report on Friday, March 6th. Finally, Truist Financial assumed coverage on shares of ArriVent BioPharma in a research note on Tuesday, November 25th. They set a “buy” rating and a $43.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $41.67.

Institutional Investors Weigh In On ArriVent BioPharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Virtus Investment Advisers LLC raised its position in shares of ArriVent BioPharma by 126.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,894 shares of the company’s stock valued at $219,000 after purchasing an additional 6,078 shares during the period. Quadrature Capital Ltd bought a new position in ArriVent BioPharma in the 4th quarter worth approximately $257,000. Persistent Asset Partners Ltd purchased a new position in ArriVent BioPharma in the 4th quarter valued at approximately $160,000. Intech Investment Management LLC purchased a new position in ArriVent BioPharma in the 4th quarter valued at approximately $221,000. Finally, Brevan Howard Capital Management LP bought a new stake in ArriVent BioPharma during the 2nd quarter valued at $209,000. 9.48% of the stock is currently owned by institutional investors.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.